Mabqi Secures $5M Grant to Accelerate Breakthrough Therapeutic Antibody Development for Oncology

Mabqi is excited to announce that the company has successfully raised $5,000,000 in its latest funding round, marking a transformative milestone in its mission to revolutionize therapeutic antibody discovery and development. Specializing in the creation of human therapeutic antibodies, Mabqi leverages its proprietary fully human libraries, including pH-sensitive variants tailored for oncology applications, to deliver innovative and effective end-to-end discovery solutions. This significant financial boost will accelerate the company’s comprehensive approach—from antibody discovery and affinity maturation to optimization and full characterization—ensuring that each project meets the highest standards of quality, developability, and clinical potential. The funds will primarily be directed towards advancing the development of new antibody candidates targeting innovative pathways in oncology. By enhancing its robust platform with additional resources, Mabqi is well-positioned to expand its pipeline and bring novel therapeutic solutions to patients who are in urgent need of more effective treatments. Moreover, the investment supports further research into off-the-shelf antibody assets, which are not only essential for rapid response to emerging therapeutic targets but also open doors for strategic partnerships and licensing opportunities. Mabqi’s commitment to scientific excellence and innovation is underscored by this financial milestone, as it continues to push the boundaries of what's possible in human therapeutic antibody development. The recent funding will drive pivotal research initiatives and support the scaling of operations, positioning Mabqi as a key player in the next wave of transformative oncology therapies.